Image For Activity Cover
2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts
Conference | English
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Contains (198)
PP01.01 (Poster) High-risk histopathological correlates of stage I non-small cell lung cancer (NSCLC) outcomes
PP01.02 (Poster) Clinical characteristics and outcomes of patients with EGFR mutated non-small cell lung cancer treated by EGFR targeted therapy then immunotherapy
PP01.05 (Poster) Treatment Patterns and Healthcare Resource Utilization of Non-small Cell Lung Cancer Patients in Puerto Rico: The TREATLINES-ONCOLUNG Study
PP01.116 (Poster) Utilization of Extended-interval, Fixed-dosing of Durvalumab, Every 4 weeks, in U.S. Patients with Unresectable Stage III NSCLC Following Concurrent Chemoradiation
PP01.07 (Poster)Agent -Based Modeling Approach for Screening Cancer Growth
PP01.09 (Poster) Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US
PP01.10 (Poster) Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
PP01.101 (Poster) Estimated Cost of Adverse Events and Surgery for Patients With Resectable Non small Cell Lung Cancer Who Are Receiving Neoadjuvant Nivolumab Plus Platinum Doublet Chemotherapy
PP01.102 (Poster) Appalachian Veterans Lung Cancer Screening Program
PP01.104 (Poster) Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases
PP01.105 (Poster) Early detection of non–small-cell lung cancer using electronic health record data
PP01.106 (Poster) Validation of Immunotherapy Response Score (IRS) for predicting pembrolizumab monotherapy benefit in first line (1L) non-small cell lung cancer (NSCLC)
PP01.107 (Poster) Patient Characteristics and Treatment Patterns in Biomarker-Selected Early Non-Small Cell Lung Cancer
PP01.108 (Poster) Randomized Control Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer
PP01.109 (Poster) Concordance of Breast Density Between Low-Dose CT and Mammogram
PP01.11 (Poster) Real-world Treatment Patterns and Outcomes Among Unresectable Stage III Non-Small Cell Lung Cancer
PP01.110 (Poster) The Relationship Between Social Determinants of Health and Treatment Patterns and Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer
PP01.111 (Poster) Phase 2a Intratumoral Large Surface Area Microparticle Paclitaxel in Stage 3/4 Lung Cancer
PP01.112 (Poster) Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study
PP01.113 (Poster) Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
PP01.114 (Poster) Outcomes of Patients Diagnosed with Lung Cancer after COVID 19 Infection
PP01.115 (Poster) Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer and HER2 Mutations
PP01.117 (Poster) Real-World Effectiveness and Safety Pro le of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer
PP01.119 (Poster) Real-World Use of Lurbinectedin in Patients With Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis
PP01.120 (Poster) Pre-diagnostic Serum Biomarkers With Prognostic Value for Lung Cancer
PP01.121 (Poster) Analysis of Degron Disruption in Small Cell Lung Cancer
PP01.122 (Poster) Inclusion of Patients with Brain Metastases and Leptomeningeal Disease in Phase 3 Lung Cancer Clinical Trials: Time for Action
PP01.124 (Poster) Impact of Comprehensive vs. Limited NGS on Time to Result and Time to Treatment in Advanced NSCLC
PP01.126 (Poster) PP01.126 Lobectomy versus Sublobar Resection in the population based Mid South Quality of Surgical Resection (MS QSR) Cohort
PP01.127 (Poster) A rare case of pulmonary enteric adenocarcinoma in a 26-year-old female non-smoker
PP01.12 (Poster) Quality of Smoking Cessation Counseling Provided by Artificial Intelligence Voice Assistants
PP01.129 (Poster) Effects of Preoperative Hematocrit Level on Perioperative Outcomes and Overall Survival after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy
PP01.13 (Poster) Healthcare Utilization Amongst Patients with NSCLC Before and After Testing with a Host Immune Classifier (HIC) in a Real-World Setting
PP01.130 (Poster) Associations between Postoperative Hematocrit Levels and Postoperative Outcomes after Robotic-Assisted Pulmonary Lobectomy
PP01.131 (Poster) The Lee Revised Cardiac Risk Index as a Predictor of Postoperative Complications and Survival after Robotic-Assisted Pulmonary Lobectomy
PP01.132 (Poster) Auto-Segmentation of Lung Tumors Using Deep Learning Engines
PP01.133 (Poster) Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real World Data in Advanced Non Small Cell Lung Cancer (aNSCLC)
PP01.134 (Poster) Pathologist Driven Reflex Testing Provides Rapid, Orthogonal Results to NSCLC Patients in Response to Comprehensive Genomic Profiling QNS
PP01.135 (Poster) Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III: A Multi Center Study
PP01.136 (Poster) Understanding Experiences of Cancer Related Fatigue in Patients with Lung Cancer After Their Cancer Treatment A Qualitative Content Analysis
PP01.137 (Poster) Survival of Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC) Diagnosed at a Safety-Net Hospital
PP01.138 (Poster) Reporting of Sociodemographic Variables in Epidemiologic Studies of Non-Small Cell Lung Cancer: A Systematic Review
PP01.139 (Poster) Cardiac Events Following Concurrent Chemotherapy and Radiation with Durvalumab Consolidation for Unresectable Non-Metastatic Non-Small Cell Lung Cancer
PP01.14 (Poster) Healthcare Utilization Amongst Patients with NSCLC Stratified by Metastatic Status Before and After Testing with a Host Immune Classifier (HIC)
PP01.140 (Poster) Patient Preferences for EGFRExon 20 Insertion-Targeted Therapies in NSCLC: A Multi-Dimensional Thresholding Analysis
PP01.15 (Poster) Healthcare Costs Amongst Patients with Non-Small Cell lung cancer (NSCLC) Before and After Testing with a Host Immune Classifier (HIC)
PP01.16 (Poster) Evaluation of Lines of Therapy Amongst Patients with NSCLC Tested with a Host Immune Classifier (HIC) in a Real-World Setting
PP01.169 (Poster) Promotion of Low-Dose Computed Tomography Screening and Blood Biomarkers in Minority Communities for Early Detection of Lung Cancer in Northern Illinois
PP01.17 (Poster) Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelioma-Like Carcinoma
PP01.170 (Poster) The Role of Fat Mass and Obesity-Associated (FTO) Gene in Non-small Cell Lung Cancer Tumorigenicity and EGFR Tyrosine Kinase Inhibitor Resistance
PP01.172 (Poster) It is never too late to quit. A review: Smoking cessation can impact outcomes at all stages
PP01.18 (Poster) Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy
PP01.19 (Poster) Comparison of AI models in Lung Cancer Diagnosis and Staging
PP01.20 (Poster) Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy
PP01.21 (Poster) Five years of operation report on asbestos-related lung cancer surveillance system centered on general hospitals in South Korea
PP01.22 (Poster) Single Institution Experience of MRI Guided Radiotherapy for Thoracic Tumors and Clinical Characteristics Impacting Treatment Duty Cycle
PP01.23 (Poster) Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer
PP01.24 (Poster) FURVENT: Global, Phase 3 Trial Testing Furmonertinib versus Chemotherapy as First Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
PP01.25 (Poster) BURDEN OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION ON PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) FROM THE PERSPECTIVE OF PATIENTS AND CAREGIVERS
PP01.26 (Poster) Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis
PP01.27 (Poster) Segmentectomy quality remains important in GGO dominant stage I lung cancer
PP01.30 (Poster) Integration of molecular cancer classification and NGS to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses eligible for KRAS inhibitors
PP01.31 (Poster) Impact of Targeted Pathology Education Designed to Address Challenges in Biomarker Testing and Treatment for NSCLC
PP01.33 (Poster) Comparison of Baseline Risk of Developing and Dying from Lung Cancer in Screen Eligible General Versus Trial Populations
PP01.34 (Poster) Quantifying Minimal Residual Disease in Patients with Limited Stage Small Cell Lung Cancer
PP01.36 (Poster) Applying a Lung Cancer Screening Model on a Real-World Population
PP01.38 (Poster) A Missed Opportunity, The Lack of Lung Cancer Clinical Trial Promotion on Instagram by NCI Designated Cancer Centers
PP01.39 (Poster) Demographic and Socioeconomic Disparities in Lung Cancer Screening Uptake: A Quantitative Analysis in the State of Indiana
PP01.40 (Poster) Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital
PP01.41 (Poster) Clinical Trial Enrollment Success of Underrepresented Patients with Lung Cancer at a Single Institution
PP01.42 (Poster) Mutation/ Co-mutation Characteristics and Clinical Outcomes for Lung Adenocarcinoma with EGFR Germline Mutations
PP01.44 (Poster) A CT IMAGING BIOMARKER FOR CD8+ LYMPHOCYTES INFILTRATION STRATIFICATION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
PP01.45 (Poster) Associations of health-related quality of life (HRQoL) with daily functioning and communication with care teams in patients with ALK+ NSCLC
PP01.46 (Poster) Real-World Rebiopsy and Biomarker Retesting Rates Among Patients With Non–Small Cell Lung Cancer Across Patient Demographics in the United States
PP01.47 (Poster) TREAT 2.0 – Creation of a Clinically Useful High-Risk Lung Nodule Calculator
PP01.49 (Poster) END TO END MODEL FOR NODULE DETECTION AND CHARACTERIZATION IN LUNG CANCER SCREENING: PERFORMANCES AND SUBPOPULATION ANALYSIS
PP01.50 (Poster) SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression and / or Amplification Post-Osimertinib
PP01.52 (Poster) The Effect of Altered RNA Expression on Tumor Immune Infiltration in NSCLC: A Retrospective NGS Study
PP01.54 (Poster) A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors
PP01.55 (Poster) Patient-reported experience as a baseline for 4R care sequence implementation at 9 cancer centers
PP01.57 (Poster) Understanding the molecular mechanism of Supinoxin on Small cell Lung Cancer Therapy
PP01.58 (Poster) Real-World Outcomes in Patients INTRODUCTION METHODS With EGFR Wildtype Nonsquamous Locally Advanced/ Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101
PP01.59 (Poster) Minimal Short-Term Mortality in a Diverse, Real-World Lung Cancer Screening Cohort
PP01.60 (Poster) Nodify Lung Risk Assessment Testing in Deciphering the Risk of Malignancy of a Lung Nodule
PP01.61 (Poster) The Use of Low-Dose Lung CT for Lung Cancer Screening in Firefighters
PP01.62 (Poster) Downregulation of Immune-Mediated Pathways in Lung Andenocarcinoma with KEAP1 or STK11 Mutation
PP01.63 (Poster) A comparative analysis of plasma genotyping practices in non-small cell lung cancer by race, ethnicity, and smoking status
PP01.64 (Poster) Disparities in the impact of advances in metastatic non-small cell lung cancer therapy on mortality in the United States
PP01.65 (Poster) Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib
PP01.66 (Poster) An unusual presentation and delayed diagnosis of multifocal lung adenocarcinoma
PP01.67 (Poster) Evaluating Immune-Related Adverse Events in A Real-world Cohort with Lung Cancer Receiving Immunotherapy
PP01.68 (Poster)Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
PP01.69 (Poster) Atypical Lung Carcinoids with EML4::ALK Fusion and Responses to ALK Inhibitors
PP01.70 (Poster) Next Generation of Bronchoscopy for Diagnostic Evaluation of Non-Small Cell Lung Cancer
PP01.71 (Poster) Clinicopathologic Profile of Filipino Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer: A Single Institution Review
PP01.72 (Poster) Trial in Progress: Randomized Phase 3 Study of Tarlatamab, a DLL3-Targeting BiTE® (Bispecific T-cell Engager) Immunotherapy, Compared to Standard of Care in Patients With Relapsed Small Cell Lung Cancer (DeLLphi-304)
PP01.74 (Poster) LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study
PP01.76 (Poster) Optimizing Biomarker Models for Biologically-Heterogeneous Cancers: A Nested Model Approach for Lung Cancer
PP01.77 (Poster) Biomarker testing in lung cancer: perspectives and challenges concerning internal, external and reflexive testing processes in an academic medical center
PP01.78 (Poster) First-line nivolumab + ipilimumab + chemotherapy in metastatic non-small cell lung cancer: CheckMate 9LA 4-year clinical update
PP01.78 Faris Badin Abstract
PP01.79 (Poster) ctDNA dynamics, prognostic markers, and RESULTS mechanisms of resistance in tepotinib-treated MET exon 14 skipping (METex14) NSCLC in the VISION trial
PP01.80 (Poster) A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK+ non-small celllung cancer (NSCLC) treated with ALK inhibitors
PP01.81 (Poster) REZILIENT2: Phase 2 Study of Zipalertinib in Patients With Advanced NSCLC With Exon 20 Insertions and Other Uncommon EGFR Mutations
PP01.8 (Poster) Tumor-naïve pre-surgical ctDNA detection is prognostic in stage I lung adenocarcinoma, associating with PD-L1 positivity and high-grade histological subtype
PP01.83(Poster) Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
PP01.84 (Poster) Tepotinib + osimertinib in EGFR mutant NSCLC with MET amplification following 1L osimertinib: INSIGHT 2 primary analysis
PP01.85 (Poster) A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer
PP01.86 (Poster) Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
PP01.88 (Poster) REZILIENT3: Phase 3 Study of Zipalertinib Plus Chemotherapy in Previously Untreated, Advanced, Nonsquamous NSCLC Patients With EGFR Exon 20 Insertions
PP01.89 (Poster) Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC
PP01.90 (Poster) Real-world demographics, clinical characteristics, treatment patterns and clinical outcomes for US patients with limited-stage small-cell lung cancer
PP01.91 (Poster) Repotrectinib in patients with ROS1 fusion‑positive non‑small cell lung cancer: update from the pivotal phase 1 / 2 TRIDENT‑1 trial
PP01.92 (Poster) Analytical Performance of a Cell-free DNA Targeted Methylation Test for Early Lung Adenocarcinoma (LUAD) Recurrence Prediction
PP01.93 (Poster) RET Fusion as a Treatable Resistance Mechanism in EGFR Mutation Lung Cancer - A Case Report
PP01.95 (Poster) STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer
PP01.96 (Poster) Characterization of DNA damage repair mutations in lung cancer in an underserved urban patient population
PP01.97 (Poster) Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab
PP01.99 (Poster) Switching to Subcutaneous Atezolizumab After Intravenous Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
PP01.001 Margaret Locke Abstract
PP01.002 Antonious Hazim Abstract
PP01.026 David Xiao Abstract
PP01.041 Christopher Zazueta NACLC23 Abstract
PP01.042 Kelsey Pan NACLC23 Abstract
PP01.044 Fadila Zerka NACLC23 Abstract
PP01.046 Aida Myftiu NACLC Abstract
PP01.047 Palina Woodhouse NACLC23 Abstract
PP01.050 Zofia Piotrowska NACLC23 Abstract
PP01.052 Tyler Faith NACLC23 Abstract
PP01.053 Winston Gouldin NACLC23 Abstract
PP01.054 Jun Zhang Abstract
PP01.055 Frank Weinberg NACLC23 Abstract
PP01.057 Subhadeep Das NACLC23 Abstract
PP01.058 Qingqing Xu NACLC23 Abstract
PP01.059 Mary Gwin NACLC23 Abstract
PP01.060 Vershalee Shukla NACLC23 Abstract
PP01.061 Vershalee Shukla NACLC23 Abstract
PP01.063 Vivian Altiery De Jesus NACLC Abstract
PP01.064 Maxwell Akanbi NACLC23 Abstract
PP01.065 Justin Cheung NACLC23 Abstract
PP01.066 Shruti_Gupta_NACLC23_Abstract
PP01.067 Xiao Hu NACLC23 Abstract
PP01.068 Alexander Spira NACLC23 Abstract
PP01.069 Sarah Waliany NACLC23 Abstract
PP01.070 Sylvia Yong NACLC23 Abstract
PP01.071 Kenneth Samala NACLC23 Abstract
PP01.072 Hossain Borghaei NACLC23 Abstract
PP01.074 Jens Samol NACLC23 Abstract
PP01.076 Palina Woodhouse NACLC23 Abstract
PP01.077 Marie Dreyer NACLC23 Abstract
PP01.080 Josh Biber NACLC23 Abstract
PP01.081 John Heymach NACLC23 Abstract
PP01.082 Tae Hee Hong NACLC23 Abstract
PP01.083 Matthew Lee_NACLC23 Abstract
PP01.084 Richard O' Hara_NACLC23 Abstract
PP01.088 John Heymach NACLC23 Abstract
PP01.090 Anne Chiang NACLC Abstract
PP01.092 Mahami Roychowdhury-Saha Abstract
PP01.093 Vivek Athipatla NACLC23 Abstract
PP01.094 Arvind Kumar NACLC2023 Abstract
PP01.095 Daniel Simmons NACLC23 Abstract
PP01.096 Jeremy Kao NACLC23 Abstract
PP01.097 Husam_Albarmawi_NACLC23_Abstract
PP01.098 Charles Logan NACLC23 Abstract
PP01.099 Stephanie Liu Abstract
PP01.100 Daniel Principe Abstract
PP01.101 Paul Lozowicki Abstract
PP01.102 Sabrina Thomas NACLC Abstract
PP01.104 Peony Yu Abstract
PP01.105 Melissa Santorelli Abstract
PP01.106 Brandi Oakley Abstract
PP01.107 Jesse Sussell Abstract
PP01.108 Mariana Borras Osorio Abstract
PP01.109 Lauren Lentini Abstract
PP01.110 Umit Tapan NACLC23 Abstract
PP01.112 Davey Daniel NACLC23 Abstract
PP01.114 Zaid Al-Saheli NACLC23 Abstract
PP01.115 Christina Baik NACLC Abstract
PP01.116 Reina Haque NACLC23 Abstract
PP01.117 Apar Ganti NACLC23 Abstract
PP01.119 Firas Badin NACLC23 Abstract
PP01.120 Patrick_Meyers_NACLC23_Abstract
PP01.121 Kim Lauer NACLC23 Abstract
PP01.122 Ivy Riano NACLC23 Abstract
PP01.124 Danielle Dressler NACLC23 Abstract
PP01.126 Raymond Osarogiagbon Abstract
PP01.128 Seana Corbin NACLC23 Abstract
PP01.129 Eric Toloza NACLC23 Abstract (PreopHematocrit)
PP01.130 Eric Toloza NACLC23 Abstract (PostopHematocrit)
PP01.131 Eric Toloza NACLC23 Abstract (LCRI)
PP01.132 Yaqi Miao NACLC23 Abstract
PP01.133 Kate Lovett NACLC23 abstract
PP01.134 Michelle Shiller NACLC23 Abstract
PP01.135 Philip Young NACLC23 Abstract
PP01.136 Beom-joon Lee NACLC23 Abstract
PP01.137 Priyanka Reddy NACLC23 Abstract
PP01.138 Kelly Meza Abstract
PP01.140 Eileen Curran NACLC23 Abstract
Powered By